| 摘要 |
The present invention relates to a method for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor such as sunitinib. More specifically, the method of the invention comprises a step of determining the expression level of one or two markers selected in the group consisting of the VEGF 121 or VEGF 165 isoforms in a biological sample obtained from said patient.
|
